Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Tarhini, Ahmad A.
Butterfield, Lisa H.
Kirkwood, John M.
Funding for this research was provided by:
National Institutes of Health (P50CA121973)
Text and Data Mining valid from 2015-09-15
19 May 2015
10 July 2015
15 September 2015